Mookadam Farouk, Moustafa Sherif E
Department of Cardiovascular Diseases, Mayo College of Medicine, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA.
Curr Heart Fail Rep. 2009 Dec;6(4):245-53. doi: 10.1007/s11897-009-0034-4.
Cardiac remodeling remains an important primary therapeutic target in patients with myocardial infarction (MI) and chronic heart failure. It also has utility as a reliable surrogate for clinical outcomes. The past three decades of research have demonstrated the importance of cardiac remodeling as a basic mechanism in the progression of heart failure. Novel therapeutic advances have allowed more patients to survive acute MI. Strategies to prevent or halt adverse left ventricular remodeling have included pharmacotherapy, percutaneous interventions, device-based therapies, and surgical procedures. More recently, experimental research has added opportunities for novel approaches to prevent and reverse cardiac remodeling. This review summarizes the effects of current and future therapeutic strategies on left ventricular remodeling and dysfunction after MI.
心脏重塑仍然是心肌梗死(MI)和慢性心力衰竭患者重要的主要治疗靶点。它也可作为临床结局的可靠替代指标。过去三十年的研究表明,心脏重塑作为心力衰竭进展的一种基本机制具有重要意义。新的治疗进展使更多患者在急性心肌梗死后存活下来。预防或阻止不良左心室重塑的策略包括药物治疗、经皮介入治疗、基于器械的治疗和外科手术。最近,实验研究为预防和逆转心脏重塑的新方法提供了机会。本综述总结了当前和未来治疗策略对心肌梗死后左心室重塑和功能障碍的影响。